ARTV
Live chart
What they do
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis.
For information only · Important disclosures
Grades vs sector
No sector grades for ARTV yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2025-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Quality & financial health
Piotroski F-score 2/9 · last two fiscal years
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $0 | $-83.9M | $-79.3M |
| 2024 | $251.0K | $-65.4M | $-55.7M |
| 2023 | $33.5M | $-28.7M | $-50.7M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.64 | -0.63 | +1.9% |
| 2026-05-08 | -0.84 | -0.95 | -12.7% |
| 2026-03-10 | -0.80 | -0.84 | -5.0% |
| 2025-11-12 | -0.80 | -0.88 | -10.0% |
| 2025-08-06 | -0.77 | -0.87 | -13.0% |
| 2025-05-08 | -0.62 | -0.83 | -33.9% |
| 2024-11-12 | -0.63 | -0.87 | -37.5% |
| 2024-08-29 | -1.59 | -0.64 | +59.9% |
Insider trades
$168.9K
$421.8K
$7.5K
$57.2K
$70.7K
$255.7K
$690.4K
$12.3K
$93.6K
$115.6K
$98.7K
$5.1K
Stats refreshed 2026-10-21 18:00:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026